Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.
Huang H, Peng L, Zhang B, Till BG, Yang Y, Zhang X, Zhao L, Fu X, Li T, Han L, Qin P, Chen L, Yan X, Liu Y, Wang W, Ye Z, Li H, Gao Q, Wang Z.
Huang H, et al. Among authors: fu x.
Front Immunol. 2022 Jul 13;13:882172. doi: 10.3389/fimmu.2022.882172. eCollection 2022.
Front Immunol. 2022.
PMID: 35911715
Free PMC article.